4D Molecular Therapeutics stock rises on $85 million Otsuka deal
PositiveFinancial Markets

4D Molecular Therapeutics has seen a significant boost in its stock value following an $85 million deal with Otsuka. This partnership is expected to enhance their research and development capabilities, which could lead to groundbreaking advancements in gene therapy. Investors are optimistic about the potential for increased revenue and innovation, making this a noteworthy development in the biotech sector.
— Curated by the World Pulse Now AI Editorial System










